MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy targets Hard-to-Treat KRAS cancers in early trial
Disease control CompletedThis early-phase trial tested a new immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy combines an immune booster with cancer-specific pep…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 23, 2026 18:12 UTC
-
Immunotherapy targets 'Invisible' leukemia to stop relapse
Disease control CompletedThis phase II trial tested blinatumomab in 36 adults with B-cell acute lymphoblastic leukemia who were in remission but still had tiny amounts of leukemia cells (minimal residual disease). The drug is an immunotherapy that helps the body's immune system find and destroy these hid…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
Can zapping cancer spots delay lung cancer progression?
Disease control CompletedThis study tested whether a procedure called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows signs of remaining cancer (minimal residual disease, or MRD). 37 patients with stage IV NSCLC received LAT to all visib…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Immune cells take on tough leukemia in early trial
Disease control CompletedThis early-phase study tested a new treatment using lab-grown immune cells (iPSC NK cells) in 2 adults with hard-to-treat acute myeloid leukemia (AML) or signs of remaining disease after treatment. The main goal was to check safety and find the right dose. Researchers also looked…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC